Brief: Pulmatrix Announces Submission Of IND Application To FDA
11/07/2023 14:06
July 11 (Reuters) - Pulmatrix Inc PULM.O :
* PULMATRIX ANNOUNCES SUBMISSION OF IND APPLICATION TO FDA
TO
INITIATE A PHASE 2 TRIAL OF INVESTIGATIONAL DRUG PUR3100 TO
TREAT ACUTE MIGRAINE
Source text for Eikon: ID:nPnT8ffLa
Further company coverage: PULM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pulmatrix
See all newsBrief: Pulmatrix Announces Second Quarter 2026 Financial Results And Progress On Merger
Pulmatrix Q2 loss narrows on clinical development hold
Pulmatrix Q1 net loss narrows, clinical development on hold
Brief: Pulmatrix Announces Closing Of Preferred Stock Transaction As Part Of Planned Merger
NASDAQ RESUMED AT 09:00 AM